UY28335A1 - Nueva combinación - Google Patents

Nueva combinación

Info

Publication number
UY28335A1
UY28335A1 UY28335A UY28335A UY28335A1 UY 28335 A1 UY28335 A1 UY 28335A1 UY 28335 A UY28335 A UY 28335A UY 28335 A UY28335 A UY 28335A UY 28335 A1 UY28335 A1 UY 28335A1
Authority
UY
Uruguay
Prior art keywords
new combination
active ingredient
receptor antagonist
tnfa
kit
Prior art date
Application number
UY28335A
Other languages
English (en)
Inventor
Nigel Boughton-Smith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312321A external-priority patent/GB0312321D0/en
Priority claimed from SE0301655A external-priority patent/SE0301655D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28335A1 publication Critical patent/UY28335A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La invención proporciona un producto farmacéutico o kit que comprende un primer ingrediente activo que es un antagonista del receptor P2X, siendo dicho antagonista del receptor P2X, es un derivado de adamantilo y un segundo ingrediente activo que es un inhibidor del factor de necrosis tumoral a (TNFa), para uso en el tratamiento de trastornos inflamatorios.
UY28335A 2003-05-29 2004-05-28 Nueva combinación UY28335A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312321A GB0312321D0 (en) 2003-05-29 2003-05-29 New combination
SE0301655A SE0301655D0 (sv) 2003-06-05 2003-06-05 New combination

Publications (1)

Publication Number Publication Date
UY28335A1 true UY28335A1 (es) 2004-12-31

Family

ID=33492248

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28335A UY28335A1 (es) 2003-05-29 2004-05-28 Nueva combinación

Country Status (15)

Country Link
US (1) US20070032465A1 (es)
EP (1) EP1633401A1 (es)
JP (1) JP2007501270A (es)
KR (1) KR20060037258A (es)
AR (1) AR044452A1 (es)
BR (1) BRPI0410739A (es)
CA (1) CA2526883A1 (es)
CO (1) CO5640094A2 (es)
IS (1) IS8188A (es)
MX (1) MXPA05012705A (es)
NO (1) NO20056131L (es)
RU (1) RU2350354C2 (es)
TW (1) TW200507829A (es)
UY (1) UY28335A1 (es)
WO (1) WO2004105798A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
CN101171221A (zh) * 2005-03-07 2008-04-30 甘加·拉祖·戈卡拉祖 新的乳香酸盐和选择性富集的乳香酸以及它们的制备方法
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
WO2011109833A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
US9538710B2 (en) 2010-04-01 2017-01-10 Tony Wayne Covely Crop product tracking system and method
US10444122B2 (en) 2010-04-01 2019-10-15 Agri-Labs Holdings Llc Soil sample tracking system and method
CN103841969A (zh) * 2011-08-04 2014-06-04 美国卫生和人力服务部 经由药物介导的对类二十烷酸平衡的操作治疗和预防微生物介导的疾病
EP3427721A1 (en) 2012-05-18 2019-01-16 Genentech, Inc. High-concentration monoclonal antibody formulations
KR102035463B1 (ko) * 2018-02-14 2019-11-26 연세대학교 산학협력단 암 줄기세포의 치료용 약학 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
SK283162B6 (sk) * 1996-05-20 2003-03-04 Darwin Discovery Limited Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
RU2254333C2 (ru) * 1999-04-09 2005-06-20 Астразенека Аб Производные адамантана, способ их получения, фармацевтическая композиция на их основе и способы лечения
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
KR100908468B1 (ko) * 2001-07-02 2009-07-21 엔.브이.오가논 테트라히드로퀴놀린 유도체
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
BRPI0410739A (pt) 2006-06-27
TW200507829A (en) 2005-03-01
CA2526883A1 (en) 2004-12-09
WO2004105798A1 (en) 2004-12-09
NO20056131L (no) 2006-02-28
IS8188A (is) 2005-12-20
JP2007501270A (ja) 2007-01-25
US20070032465A1 (en) 2007-02-08
RU2350354C2 (ru) 2009-03-27
CO5640094A2 (es) 2006-05-31
EP1633401A1 (en) 2006-03-15
MXPA05012705A (es) 2006-02-08
AU2004243137A1 (en) 2004-12-09
RU2005136131A (ru) 2006-07-27
AR044452A1 (es) 2005-09-14
KR20060037258A (ko) 2006-05-03

Similar Documents

Publication Publication Date Title
UY28335A1 (es) Nueva combinación
AR059203A1 (es) Composiciones para uso vaginal
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
MX2022002633A (es) Mimeticos de hepcidina conjugada.
AR037109A1 (es) Uso de flibanserina
CY1115004T1 (el) Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ
CL2009001936A1 (es) Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006).
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
UY28342A1 (es) Nuevos compuestos
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
HN2002000266A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
NO20082376L (no) Farmasoytiske sammensetninger
WO2006002057A3 (en) Treatment of acne
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
AR058308A1 (es) Fragmentos vip y metodos de uso de los mismos
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
UY29952A1 (es) Composiciones faramacéuticas que comprenden 4-(4-fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-7-(3-(pirrolidin-1-il)propoxi)quinazolina o una sal farmacéuticamente aceptable del mismo, procesos de preparación y uso
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
GT200600123A (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
ATE500835T1 (de) Entzündungshemmende zusammensetzungen und anwendungsverfahren